Cannara Biotech (TSXV:LOVE) Debt-to-Equity : 0.62 (As of Feb. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Debt-to-Equity?

Cannara Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$43.81 Mil. Cannara Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$5.64 Mil. Cannara Biotech's Total Stockholders Equity for the quarter that ended in Feb. 2024 was C$79.34 Mil. Cannara Biotech's debt to equity for the quarter that ended in Feb. 2024 was 0.62.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cannara Biotech's Debt-to-Equity or its related term are showing as below:

TSXV:LOVE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.28 Med: 0.49 Max: 0.88
Current: 0.62

During the past 6 years, the highest Debt-to-Equity Ratio of Cannara Biotech was 0.88. The lowest was 0.28. And the median was 0.49.

TSXV:LOVE's Debt-to-Equity is ranked worse than
72.37% of 847 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs TSXV:LOVE: 0.62

Cannara Biotech Debt-to-Equity Historical Data

The historical data trend for Cannara Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Debt-to-Equity Chart

Cannara Biotech Annual Data

Trend

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Debt-to-Equity

Get a 7-Day Free Trial

0.28

0.34

0.33

0.73

0.57

Cannara Biotech Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Debt-to-Equity	Get a 7-Day Free Trial															0.60	0.59	0.57	0.59	0.62

Competitive Comparison of Cannara Biotech's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannara Biotech's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Debt-to-Equity falls into.

Cannara Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cannara Biotech's Debt to Equity Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.045	+	39.739)	/	79.744
	=	0.57

Cannara Biotech's Debt to Equity Ratio for the quarter that ended in Feb. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(43.813	+	5.636)	/	79.34
	=	0.62

Cannara Biotech (TSXV:LOVE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cannara Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech (TSXV:LOVE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

LOVFF:USA 8CB0:Germany

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

Executives